首页> 外文期刊>Peptides: An International Journal >The bombesin/gastrin releasing peptide receptor antagonist RC-3095 blocks apomorphine but not MK-801-induced stereotypy in mice.
【24h】

The bombesin/gastrin releasing peptide receptor antagonist RC-3095 blocks apomorphine but not MK-801-induced stereotypy in mice.

机译:轰击蛋白/胃泌素释放肽受体拮抗剂RC-3095阻断阿扑吗啡,但不阻断MK-801诱导的小鼠定型。

获取原文
获取原文并翻译 | 示例
           

摘要

Bombesin (BN)-like peptides might be involved in the pathogenesis of neuropsychiatric disorders such as schizophrenia. Stereotyped behaviors induced by the dopamine receptor agonist apomorphine or the N-methyl-D-aspartate glutamate receptor antagonist dizocilpine (MK-801) in rodents have been proposed as animal models of schizophrenic psychosis. In the present study we evaluated the effects of the BN/gastrin-releasing peptide receptor (GRP) antagonist (D-Tpi6, Leu13 psi[CH2NH]-Leu14) bombesin (6-14) (RC-3095) on apomorphine and MK-801-induced stereotyped behavior in mice. An intraperitoneal (i.p.) injection of RC-3095 (1.0, 10.0 or 100.0 mg/kg) blocked apomorphine-induced stereotypy. The inhibitory effect of RC-3095 on apomorhine-induced stereotypy was similar to that induced by haloperidol (0.5 mg/kg). RC-3095 did not affect stereotyped behavior induced by MK-801 (0.5 mg/kg). The results provide the first evidence that BN/GRP receptor antagonism blocks stereotyped behavior induced by a dopamine agonist. Together with previous evidence, the present study indicates that the BN/GRP receptor can be considered a drug target in the investigation of potential new agents for treating neuropsychiatric disorders.
机译:Bombesin(BN)样肽可能与神经精神疾病(例如精神分裂症)的发病机理有关。多巴胺受体激动剂阿扑吗啡或N-甲基-D-天冬氨酸谷氨酸受体拮抗剂地佐西平(MK-801)在啮齿动物中引起的定型行为已被提议作为精神分裂症精神病的动物模型。在本研究中,我们评估了BN /胃泌素释放肽受体(GRP)拮抗剂(D-Tpi6,Leu13 psi [CH2NH] -Leu14)轰击蛋白(6-14)(RC-3095)对阿扑吗啡和MK-的作用801在小鼠中的定型行为。腹膜内(i.p.)注射RC-3095(1.0、10.0或100.0 mg / kg)可阻断阿扑吗啡引起的刻板印象。 RC-3095对阿扑吗啡引起的刻板印象的抑制作用与氟哌啶醇(0.5 mg / kg)相似。 RC-3095不会影响MK-801(0.5 mg / kg)所致的刻板行为。该结果提供了第一个证据,表明BN / GRP受体拮抗作用可阻断多巴胺激动剂诱导的定型行为。与以前的证据一起,本研究表明,在研究潜在的治疗神经精神疾病的新药方面,可以将BN / GRP受体视为药物靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号